Powles R L, Morgenstern G R, Leigh M, Filshie J, Platt J, Lumley H
Haematol Blood Transfus. 1983;28:87-9. doi: 10.1007/978-3-642-68761-7_19.
One hundred and nineteen patients with leukaemia have received CSA as prophylaxis against acute GVHD following sibling MHC matched (84) or family member mismatched bone marrow transplants (35). four recipients of matched transplants (3%) died of acute GVHD, a marked improvement on our previous results using methotrexate (26 patients; 27% died of GVHD). Thirty-five patients received mismatched transplants, 15 were under the age of 20 years and eight are alive and in remission, the longest survivor being one at 2 1/2 years after transplant.
119例白血病患者在接受同胞人类白细胞抗原（MHC）匹配（84例）或家庭成员不匹配的骨髓移植（35例）后，接受环孢素A（CSA）预防急性移植物抗宿主病（GVHD）。4例匹配移植受者（3%）死于急性GVHD，与我们之前使用甲氨蝶呤的结果相比有显著改善（26例患者；27%死于GVHD）。35例患者接受了不匹配移植，其中15例年龄在20岁以下，8例存活且处于缓解期，移植后最长存活者为1例，已存活2年半。
